The clinical efficacy of immuno-oncology (IO) agents that inhibit the programmed death 1 (PD-1)-programmed death ligand 1 (PD-L1) signaling pathway in advanced NSCLC has been described. Here, CD274 is linked to non-small cell lung carcinoma.